ReviewCancers2022
Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Microbiome and pancreatic ductal adenocarcinoma: mechanistic insights, microenvironmental interactions, and therapeutic implications.Molecular biology reports · 2026Review
- Article
- Strategic modulation of the gastrointestinal microbiome to enhance pancreatic cancer immunotherapy.Drug discovery today · 2025Review
- Comparative Analysis of Fecal Microbiota in Healthy Controls and Pancreatic Cancer Patients: A Focus on Tumor Localization Differences in Pancreatic Head and Body-Tail.Cancer medicine · 2025Article
- Gastric Cancer and Microbiota: Exploring the Microbiome's Role in Carcinogenesis and Treatment Strategies.Life (Basel, Switzerland) · 2025Review
- Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug.Biomedicines · 2025Review
- Oral microbiome as a diagnostic biomarker for pancreatic cancer: a systematic review and meta-analysis of diagnostic accuracy.Journal of oral microbiology · 2025Review
- Skin microbiome differences in pancreatic adenocarcinoma, other cancers, and healthy controls: a pilot study.Frontiers in oncology · 2025Article
- Heterogeneous changes in gut and tumor microbiota in patients with pancreatic cancer: insights from clinical evidence.BMC cancer · 2024Article
- Article
- Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights.World journal of gastroenterology · 2023Review
- Advances in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma and Premalignant Pancreatic Lesions.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early microbiome insights came from gut microbes and their role among intestinal and extraintestinal disease. The latest evidence suggests that the microbiota is a true organ, capable of several interactions throughout the digestive system, attracting specific interest in the biliopancreatic district. Despite advances in diagnostics over the last few decades and improvements in the management of this disease, pancreatic cancer is still a common cause of cancer death. Microbiota can influence the development of precancerous disease predisposing to pancreatic cancer (PC). At the same time, neoplastic tissue shows specific characteristics in terms of diversity and phenotype, determining the short- and long-term prognosis. Considering the above information, a role for microbiota has also been hypothesized in the different phases of the PC approach, providing future revolutionary therapeutic insights. Microbiota-modulating therapies could open new issues in the therapeutic landscape. The aim of this narrative review is to assess the most updated evidence on microbiome in all the steps regarding pancreatic adenocarcinoma, from early development to response to antineoplastic therapy and long-term prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.